SynthesisBreast cancer research and treatment2018
Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis.
Synthesis in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Pooled it
- Prevalence of and factors associated with treatment modification at first cycle in older adults with advanced cancer receiving palliative treatment.Journal of geriatric oncology · 2021Trial
- Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study.Breast cancer research and treatment · 2026Article
- Tumor biology and access to care and metastatic breast cancer outcomes.Breast cancer research and treatment · 2025Article
- Connecting algorithmic fairness and fair outcomes in a sociotechnical simulation case study of AI-assisted healthcare.Nature communications · 2025Article
- The impact of adjuvant chemotherapy on overall survival in premenopausal (age ≤ 50 years) hormone and node positive breast cancer patients with an Oncotype Dx score of 25 or less. A NCDB analysis.Breast cancer research and treatment · 2025Article
- Predictors of Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer.Annals of surgical oncology · 2025Article
- Low Socioeconomic Status at the Patient and Institutional Level Impact Achievement of Breast Cancer Quality Standards.Annals of surgical oncology · 2025Article
- Annals of Surgical Oncology Landmark Series Disparities in Surgical Oncology: Breast Cancer.Annals of surgical oncology · 2025Review
- Treatment Patterns, Trends, and Outcomes of Neoadjuvant Chemotherapy Use Among Patients With Early-Stage Invasive Triple-Negative Breast Cancer.JCO oncology practice · 2025Article
- Applying a Novel Measure of Community-Level Healthcare Access to Assess Breast Cancer Care Timeliness.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Are there differences in overall survival among older breast cancer patients by race and ethnicity?Surgery · 2025Article
- Racial disparities in triple-negative breast cancer: insights from the E5103 trial and beyond.Gland surgery · 2025Article
- A latent class assessment of healthcare access factors and disparities in breast cancer care timeliness.PLoS medicine · 2024Article
- Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- An elevated rate of whole-genome duplications in cancers from Black patients.Nature communications · 2024Article
- Surgeon and Care Team Network Measures and Timely Breast Cancer Treatment.JAMA network open · 2024Article
- Simulating the population impact of interventions to reduce racial gaps in breast cancer treatment.Journal of the National Cancer Institute · 2024Article
- Article
- Challenges Experienced by Black Women with Breast Cancer During Active Treatment: Relationship to Treatment Adherence.Journal of racial and ethnic health disparities · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
purposeWe conducted a systematic review and meta-analysis to measure the extent to which race is associated with delayed initiation or receipt of inadequate chemotherapy among women with early-stage breast cancer.
methodsWe performed a systematic search of all articles published from January 1987 until June 2017 within four databases: PubMed/Medline, EMBASE, CINAHL, and Cochrane CENTRAL. Eligible studies were US-based and examined the influence of race on chemotherapy delays, cessation, or dose reductions among women with stage I, II, or III breast cancer. Data were pooled using a random effects model.
resultsA total of twelve studies were included in the quantitative analysis. Blacks were significantly more likely than whites to have delays to initiation of adjuvant therapy of 90 days or more (OR 1.41, 95% CI 1.06-1.87; X² = 31.05, p < 0.00001; I² = 90%). There was no significant association between race and chemotherapy dosing. Due to overlap between studies assessing the relationship between race and completion of chemotherapy, we conducted two separate analyses. Black patients were significantly more likely to discontinue chemotherapy, however, this was no longer statistically significant when larger numbers of patients with more advanced (stage III) breast cancer were included.
conclusionsThese results suggest that black breast cancer patients experience clinically relevant delays in the initiation of adjuvant chemotherapy more often than white patients, which may in part explain the increased mortality observed among black patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.